U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07107126) titled 'Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes' on July 30.
Brief Summary: The main goals of this study are to learn if RPT1G is safe and tolerable and to determine the best dose and schedule of RPT1G for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Study Start Date: Dec. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Intervention:
DRUG: RPT1G
RPT1G is a selective hyperbolic NAMPT inhibitor. RPT1G is administered orally.
Recruitment Status...